The
transformational effect of photoredox catalytic chemistries
has inspired new opportunities, enabling us to interrogate nature
in ways that are not possible otherwise and to unveil new biotechnologies
in therapy and diagnosis. However, the deployment of artificial photoredox
catalysis in living systems remains challenging, mired by the off-target
risk and safety concerns of photocatalyst toxicity. Here, we present
an appealing approach, namely conditionally activatable photoredox
catalysis (ConAPC), and as a proof of concept design the first ConAPC
architecture (Se-NO
2
) based upon
classic self-immolative chemistry, in which the inherent photocatalytic
properties can be temporarily caged while the species becomes active
only at the tumor sites via sensing to specific biomarkers. Such a
masking strategy allows a spatial–temporal control of photoresponsivity in vitro and in vivo. In particular, for
ConAPC design, a new biologically benign metal-free photocatalyst
(Se-NH
2
), which is able to initiate
NIR photoredox catalysis to manipulate the cellular electron pool
in an O2-independent mechanism of action, is identified.
With this unique strategy, potent tumor-specific targeting photocatalytic
eradication (TGI: 95%) is obtained in a mouse model. Impressively,
favorable features such as high-resolution tumor recognition (SBR:
33.6) and excellent biocompatibility and safety are also achieved.
This work therefore offers a new possibility for chemists to leverage
artificial photocatalytic reactions toward the development of facile
and intelligent photocatalytic theranostics.